Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

All

Indonesian Journal of Cancer

ijoc
Website

Published by National Cancer Center-Dharmais Cancer Hospital

ISSN : 19783744 EISSN : 23556811 DOI : https://www.doi.org/ 10.33371

Core Subject : Health, Science,

Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health

Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.

Arjuna Subject : Kedokteran - Onkologi

Articles 562 Documents

29 30 31 32 33

Karakteristik Leukemia Limfoblastik Akut pada Anak di Rumah Sakit Kanker Dharmais 2000-2008 ANKY TRI RINI; MURURUL AISY; YUNI ASRI; EDI -
Indonesian Journal of Cancer Vol 4, No 4 (2010): Oct - Dec 2010
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v4i4.122

Acute lymphoblastic leukemia (ALL) is the most common cancer found in children below 14 years old. It characterized by abnormal white blood cell proliferation which replace normal bone marrow component with pallor, headache, organomegaly, fever, bone pain and bleeding as its clinical manifestation. Acute lymphoblastic Leukemia (ALL) is very important problem in childhood cancer. As one strategy to improve cancer management, specially ALL, epidemiology description and patient outcome is needed. Based on our study in Dharmais Cancer Hospital (2000-2008), ALL is frequent in boy and particularly lie between 1-5 years old. ALL L1 is the most common type of ALL, and majority cases are standard risk. We observed 44,9% mortality,survive 27,5 %. Unfortunately there were many patients loss to follow up (27,5%) and event free survival rates for ALL in Dharmais Cancer Hospital is 38,1%.

The Role of Febrile Neutropenia Guideline’s Implementation on Mortality Rate in Dharmais Hospital-National Cancer Center Dody Ranuhardy
Indonesian Journal of Cancer Vol 12, No 3 (2018): July-September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Introduction: Febrile neutropenia have a high morbidity and mortality impact for the patient. The mortality rate of febrile neutropenia in 2002 was 38.8%, while it was 27.3% in 2009. The difference in mortality rates could be caused by several factors such as availability of the Neutropenic Fever Management Guidelines in 2006, in addition to infrastructure, human resources and equipment. This study aims to determine the role of guideline availibility and other factors to cancer mortality rate in the immunocompromised isolation room of Dharmais Hospital. Methods: This study was a cross-sectional retrospective study which investigate mortality rates and compare with adherence to febrile neutropenia guidelines for the period 2008-2012. Data were taken from the patient's medical record file, and then analysed using univariate and bivariate analysis. Results: The mortality rate in the period 2008-2012 was 20.7%. The correlation between age, sex, and degree of risk factor on mortality was not significantly different (p=0,409, p=0,404, and p=0,324). The proportion of deaths was higher in patients borne by third parties (26.8%) than in the case of personal (10%) although not statistically significant (p=0,065). From the three types of adherence, only one had a significant effect of adherence to treatment flow (p=0,033). Conclusions: The availibility of management guideline can reduce mortality rate of febrile neutropenia even though from the three types of adherence, only one had a significant effect of adherence to treatment flow (p=0,033).

Peranan Akupunktur dalam Bidang Kanker Hasan Mihardja
Indonesian Journal of Cancer Vol 2, No 1 (2008): Jan - Mar 2008
Publisher : National Cancer Center - Dharmais Cancer Hospital

Pedoman pelatihan dasar dan keselamatan di bidang akupunktur yang diterbitkan Badan Kesehatan Dunia (WHO) antara lain mengemukakan peranan akupunktur di bidang kanker.Manfaat akupunktur di bidang kanker adalah mengurangi rasa nyeri dan mual, muntah akibat penyakit kanker ataupun sebagai efek samping pengobatan konvensional kanker. Xerosthalmia paska radiasi dan hot flash yang timbul setelah pengobatan hormon juga menunjukan perbaikan setelah tindakan akupunktur. Kecermatan dalam hal dalamnya serta arah penusukan perlu diperhatikan untuk menghindari tertusuknya organ dalam misalnya pneumotorak, penggunaan elektro akupunktur cenderung merugikan penderita.Kata kunci: akupunktur, kanker, keselamatan.

Stereotactic Ablative Body Radiotherapy (SABR) in The Management Spinal Metastases: A Brief Overview* HENRY KODRAT; SOEHARTATI GONDHOWIARDJO
Indonesian Journal of Cancer Vol 11, No 1 (2017): Jan-Mar
Publisher : National Cancer Center - Dharmais Cancer Hospital

It is well known that radiotherapy provides successful pain relief in bone metastases. Advancements in imaging and radiotherapy delivery technology have enabled safe delivery of higher dose radiotherapy, which will produce more durable tumor control. Over the last decades stereotactic radiosurgery (SRS), which delivers high dose radiation, has been successfully used for the treatment of intracranial lesions. The good results obtained in SRS have led to development of extra cranial stereotactic radiosurgery known as stereotactic ablative body radiotherapy (SABR). This review paper enlightens indication, target definition, efficacy and toxicity in spinal SABR.ABSTRAK Radioterapi telah terbukti sebagai modalitas yang dapat menghilangkan nyeri pada metastases tulang. Kemajuan dalam teknologi pencitraan dan pemberian radioterapi telah memungkinkan pemberian radioterapi dosis tinggi dengan aman, di mana hal ini dapat meningkatkan kontrol lokal. Selama dekade terakhir ini, stereotactic radiosurgery (SRS) yang memberikan radiasi dosis tinggi dinyatakan bermanfaat untuk tatalaksana berbagai kelainan intrakranial. Hasil cukup memuaskan yang diperoleh SRS mendorong untuk dikembangkan stereotactic radiosurgery ekstrakranial yang kemudian dikenal sebagai stereotactic ablative body radiotherapy (SABR). Tinjauan pustaka ini menjelaskan indikasi, target radiasi, efektivitas, dan efek samping pada prosedur SABR spinal.

Efek Laserpunktur pada Titik MA-TF1 Shenmen dan MA-AT Kelenjar Parotis terhadap Gejala Xerostomia Pasien Kanker Nasofaring Pasca-radioterapi ADININGSIH SRILESTARI
Indonesian Journal of Cancer Vol 9, No 1 (2015): Jan - Mar 2015
Publisher : National Cancer Center - Dharmais Cancer Hospital

ABSTRACTXerostomia (dry mouth) is a chronic & acute effect on a cancer patient who receives radiation therapy on the areas ofhead and neck. Earlier studies state that acupuncture helps to relieve the symptoms concerning cancer and xerostomiais one. Laserpuncture is an acupuncture therapy technique that uses the benefit of low energy laser beam that does notgenerate pain and is not an invasive procedure which is more comfortable for patients. This research involved 44xerostomia patients who have underwent complete radiotherapy on the minimum course of 3 months up to amaximum of 1.5 years before going through with the research; the research is clustered into ear laserpuncture and shamlaserpuncture groups. The result shows a mean Xerostomia Inventory (XI) score between two states of pre against postlaserpuncture of 3 and 6 times of treatment that were tested on case group and control group; theres a mean score oflife quality of pre treatment compared to post treatment of laserpucture on those who underwent 3 times and 6 timeslaserpucture treatment on case group and control group on every variable of life quality, except financial difficulties (FI);and there is a mean pH score on the saliva of those undergoing treatment between the states of pre and post 6 timeslaserpuncture treatment on case group and control group. From this study, we can conclude that laserpuncture on earacupoints MA-TF1 Shenmen and MA-AT parotis gland might increase saliva pH and reduce XI score, and we canconsidered as an adjuvant treatment in xerostomia on cancer patients post radiotherapy.Keyword: ear laserpuncture; xerostomia Inventory; pH saliva; life quality.ABSTRAKXerostomia (mulut kering) merupakan efek akut dan kronik pada pasien kanker yang mendapat terapi radiasi padadaerah kepala dan leher. Beberapa studi pendahuluan mengemukakan bahwa akupunktur meringankan gejala ataukeluhan yang berhubungan dengan kanker, di antaranya xerostomia. Laserpunktur merupakan teknik terapi akupunkturyang memanfaatkan sinar laser energi rendah yang tidak menimbulkan rasa nyeri serta tidak invasif sehingga lebihnyaman bagi pasien. Penelitian ini melibatkan 44 pasien xerostomia yang telah menjalani radioterapi lengkap minimal3 bulan dan maksimal 1,5 tahun sebelum mengikuti penelitian. Pasien dibagi menjadi kelompok laserpunktur telingadan kelompok laserpunktur sham. Hasil penelitian menunjukkan terdapat rerata selisih skor Xerostomia Inventory (XI)antara sebelum tindakan laserpunktur dengan setelah memperoleh tindakan laserpunktur 3 kali dan 6 kali padakelompok kasus dan kontrol. Terdapat rerata selisih skor kualitas hidup antara sebelum tindakan laserpunktur dengansetelah memperoleh tindakan laserpunktur 3 kali dan 6 kali pada kelompok kasus dan kontrol pada semua variabelkualitas hidup, kecuali variabel financial difficulties (FI). Terdapat rerata selisih pH saliva antara sebelum tindakanlaserpunktur dengan setelah memperoleh tindakan laserpunktur 6 kali pada kelompok kasus dan kontrol.Dari hasil penelitian ini dapat disimpulkan bahwa laserpunktur pada titik akupunktur telinga MA-TF1 Shenmen danMA-AT kelenjar parotis dapat meningkatkan pH saliva dan menurunkan skor XI sehingga dapat dipertimbangkansebagai salah satu penunjang pengobatan xerostomia pada pasien kanker nasofaring pasca-radioterapi.Kata Kunci: laserpunktur telinga; xerostomia Inventory; pH saliva; kualitas hidup.

Ekspresi Heat Shock Protein 70 (HSP-70) dan P53 Mutan sebagai Faktor Prediksi Operabilitas Pasca-kemoterapi Neoajuvan pada Kanker Serviks IIB ROY YUSTIN SIMANJUNTAK; BRAHMANA ASKANDAR; DYAH FAUZIAH
Indonesian Journal of Cancer Vol 6, No 4 (2012): Oct - Dec 2012
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v6i4.293

Tujuan: untuk mengetahui ekspresi HSP-70 dan p53 mutan dalam memprediksi respons operabilitas (pra-operatif) pada penderita kanker serviks IIB yang mendapatkan kemoterapi neoajuvan Paclitaxel-Platinum. Metode: penelitian ini merupakan studi analitik dengan pendekatan kasus kontrol. Ekspresi p53 mutan dan HSP 70 diperiksa dengan pengecatan imunohistokimia pada 40 potongan biopsi jaringan pasien kanker serviks IIB yang memenuhi kriteria inkluasi, yang melakukan pengobatan di RSUD dr. Soetomo, Departemen Obstetri dan Ginekologi, Fakultas Kedokteran Universitas Airlangga, Surabaya, mulai Desember 2006 hingga Juli 2011. Kriteria inklusi meliputi ukuran tumor ? 4 cm, telah dievaluasi operabilitas melalui pemeriksaan klinis dan mendapatkan kemoterapi neoajuvan Paclitaxel-Platinum (setiap 3 minggu selama 3 siklus).Hasil: dari penelitian ini didapatkan total sampel sebanyak 40 pasien yang mendapat kemoterapi neoajuvan Paclitaxel- Platinum. Dari 40 sampel tersebut, 22 (55%) pasien kanker serviks IIB memberikan respons inoperable dan 18 (45%) pasien memberikan respons operabel. Ekspresi p53 mutan terbanyak menunjukkan hasil ekspresi negatif, dengan rentang skor 0-1, yaitu sebanyak 33 (82,5%) penderita. Ekspresi positif didapatkan pada 7 (17,5%) penderita dan tidak didapatkan perbedaan yang signifikan (p 0,48; OR: 0,55 (CI 95%:0,11- 2,87)). Jumlah ekspresi HSP 70 yang positif dan negatif menunjukkan jumlah yang sama besarnya, baik pada luaran inoperabel maupun operabel, masing-masing 11 (50,0%) dan 9 (50,0%), dengan p=1,00, OR: 1,00 (CI 95%:0,289-3,48). Hubungan antara ekspresi p53 dan HSP 70 dengan operabilitas post kemoterapi neoajuvan Paclitaxel-Platinum dianalisa dengan uji Chi-square.Kesimpulannya, ekspresi HSP 70 dan p53 mutan tidak dapat memprediksi respons operabilitas pada pasien kanker serviks IIB yang mendapatkan kemoterapi neoajuvan Paclitaxel-Platinum.Kata kunci: Kanker serviks stadium IIB, kemoterapi neoajuvan Paclitaxel- Platinum, operabilitas pasca-kemoterapi neoajuvan.

Profile of Ovarian Cancer Patients In Mangusada Badung Regional Public Hospital I Gusti Ngurah Agung Trisnu Kamajaya; Bagus Ngurah Brahmantara; AA Ngurah Agung Putra Wirawan
Indonesian Journal of Cancer Vol 15, No 3 (2021): September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Ovarian cancer is still one of the neoplasms within the gynecology scope. Besides, World Health Organization (WHO) states that ovarian cancer ranks fourth cancer in women with the lowest five-year survival rate (43%). Thus, this research aims to recognize the risk factors in patients with ovarian cancer and the commonly found characteristic.Methods: This cross-sectional observational research on 29 women diagnosed with ovarian cancer observed the age, parity, body mass index (BMI), contraception, character, and stadium. The medical record samples based on patients’ registers were obtained from the Obstetrics and Gynecologic Polyclinic in Mangusada Badung Regional Public Hospital in the January–December 2019 period, and the result data were distributed using contingency tables. Results: The data dominantly diagnosed ovarian cancer, with age distribution 51-60 years (34.5%), 44.8% with obesity, 44.8% nullipara, without a history of contraceptive use, menarche within 12 years old (41.4%), diagnosed stage IIIC (42.3%), and with serous epithelial tumor subclassification (65.5%).Conclusions: Predominant ovarian cancer is found at a late stage. The most common risk factors of developing ovarian cancer, including the age of 51–60, obesity, menarche within 12 years old, and no history of hormonal contraceptive use, are consistent with this research hypothesis about risk factors dominantly found in patients with ovarian cancer

VEGF-C Serum Level as Predictor Lymph Node Metastasis in Advanced Stage Cervical Cancer PATIYUS AGUSTIANSYAH
Indonesian Journal of Cancer Vol 8, No 3 (2014): Jul - Sep 2014
Publisher : National Cancer Center - Dharmais Cancer Hospital

The aim of this study to identify correlation between VEGF-C and lymph node metastasis in advanced stage cervicalcancer in Dr. Hasan Sadikin General Hospital Bandung from April to August 2013.Cross sectional study from 30 patients diagnosed with advanced stage Cervical Cancer (IIB IVA). We performedtransperitoneal lymphadenectomy pelvic and para-aortic and measuring VEGF-C serum with ELISA priorchemoradiation.Results : 17/30 patients (56.7%) metastasis to pelvic lymph nodes and 4/30 pastients (13.3%) metastases to para-aorticlymph nodes. VEGF-C > 5333 pg/mL has a metastasis risk to pelvic lymph node 21.6 times with 94% sensitivity; 84.6%specificity; 88.9% positive predictive value; and 84.6% negative predictive value. Meanwhile VEGF-C > 8915.5 pg/mL hasa metastasis risk to para-aortic lymph node 15 times with 75% sensitivity, 100% specificity, 100% positive predictivevalue and 96.3% negative predictive value in advanced stage cervical cancer.Conclusion: a significant correlation between VEGF-C serum level with lymph node metastasis (pelvic and para-aortic)(p < 0.05)

The Expression of CXCR4 and MMP13 in Colorectal Adenocarcinoma Dukes Stage A, B, C and D Rovi Anggoro; Etty Hary Kusumastuti
Indonesian Journal of Cancer Vol 12, No 1 (2018): Jan - Mar
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Colorectal adenocarcinoma is the third most common cancer in the world with increasing incidence in Indonesia. Most presented ones were in late stage with more unfavorable prognosis. It is necessary to evaluate new markers for prognosis, identify staging and new possibilities for targeted therapy. Over-proliferating tumor cells will enhance the expression of CXCR4, a chemokine receptor. Activating CXCR4 will further activate various downstream signaling pathways, including one which will increase MMP13 secretion through MAPK/ERK signaling pathway. MMP13 then will degrade extracellular matrix, thus facilitate the migration or metastasis of tumor cells. Methods: A cross sectional study, conducted on 32 samples of colorectal adenocarcinoma. The samples were divided into four groups based on the Dukes staging system (A, B, C and D) and stained immunohistochemically with antibody against CXCR4 and MMP13. The expressions were assessed using immunoreactive score (IRS) and were statistically analyzed. Results: There were positive correlation between the expression of CXCR4 and MMP13 with Dukes staging, with rs = 0,628 and rs = 0,597, respectively. The expression of CXCR4 positively correlated with the expression of MMP13 with rs = 0,670 (p = 0,05). Conclusions: CXCR4 and MMP13 expressions were proven to correlate with the depth of invasion and migration of tumor cells in colorectal adenocarcinoma, hence could be considered as prognostic markers, however both could not be used as predictive marker for staging. Tailored therapies targeting these two proteins could be an interest for further investigation. ABSTRAKLatar Belakang: Adenokarsinoma kolorektal adalah keganasan terbanyak ketiga di dunia, dengan insidensi semakin meningkat di Indonesia. Sebagian besar kasus terdeteksi pada stadium lanjut dengan prognosis buruk. Diperlukan penemuan marker baru yang dapat membantu penentuan stadium, prognosis dan kemungkinan terapi target yang baru. Sel tumor yang berproliferasi berlebihan akan menyebabkan peningkatan ekspresi CXCR4, suatu reseptor kemokin. Aktivasi CXCR4 akan meningkatkan pelepasan proteinase MMP13 melalui jalur MAPK/ERK. MMP13 akan mendegradasi matriks ekstraseluler sehingga menyebabkan migrasi atau metastasis sel tumor. Metode: Studi cross sectional, dilakukan pada 32 sampel adenokarsinoma kolorektal. Sampel dibagi menjadi 4 grup; stadium Dukes A, B, C dan D. Dilakukan pulasan imunohistokimia dengan antibodi CXCR4 dan MMP13, ekspresi keduanya dinilai menggunakan immunoreactive score (IRS) dan dianalisis secara statistik. Hasil: Didapatkan korelasi positif bermakna antara ekspresi CXCR4 dan MMP13 dengan stadium Dukes, dengan rs = 0,628 dan rs = 0,597. Ekspresi CXCR4 berkorelasi positif dengan ekspresi MMP13 dengan rs = 0,670 (p = 0,05). Kesimpulan: Ekspresi CXCR4 dan MMP13 terbukti berkorelasi dengan kedalaman invasi dan migrasi sel ganas pada adenokarsinoma kolorektal. Keduanya dapat dipertimbangkan sebagai marker prognostik namun tidak dapat digunakan sebagai marker prediktif stadium. Targeted therapy untuk kedua protein ini menarik untuk dilakukan investigasi lebih jauh.

Correlation between Age and Body Mass Index (BMI) with Histopathological Features of Breast Cancer Patients in RSUP Haji Adam Malik Medan Harisa Mardiah; Radita Nur Anggaeni Ginting; Heru Rahmadhany; Esther Reny Deswani Sitorus
Indonesian Journal of Cancer Vol 15, No 2 (2021): June
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Breast cancer is influenced by various risk factors, including age and obesity. Older women who are overweighted and obese have a higher risk of developing breast cancer. This study aims to find the correlation between age and body mass index (BMI) with histopathological features of breast cancer patients in RSUP Haji Adam Malik Medan.Methods: This research is an analytical study using a cross-sectional design with 103 samples obtained from medical record data by random sampling. The data obtained were then adjusted to the research criteria and grouped based on predetermined variables.Results: The majority of the age group was 41-50 years (36.9%), obesity BMI (40.8%), histopathological subtype of invasive carcinoma of no special type (NST) (85.4%), and grade II (46.6%). Kruskal-Wallis test result between histopathological subtypes and breast cancer grading based on age, respectively, obtained p=0.503, r=.325; (α>0.05), and p=0.207, r=0.393; (α>0.05), while based on BMI obtained p=0.017, r=0.021; (α<0.05), and p=0.018, r=0.018; (α<0.05). The OR value (95% CI) obtained on overweight-obese BMI with invasive carcinoma NST subtype was 7.63 (7.27–14.90) and other subtypes were 2.40 (1.14–13.75), and for grades II and III, they were respectively 3.57 (1.32–8.09) and 3.27 (1.17–9.91).Conclusions: There was a correlation between BMI with histopathological subtypes and breast cancer grading, but the correlation tended to be weak. Whereas, with age, there was no correlation. BMI overweight-obese were more likely to have invasive carcinoma NST subtype and higher-grade of breast cancer.

Page 31 of 57 | Total Record : 562

29 30 31 32 33

Filter by Year

2007 2025

Filter By Issues

All Issue Vol 19, No 3 (2025): September Vol 19, No 2 (2025): June Vol 19, No 1 (2025): March Vol 18, No 4 (2024): December Vol 18, No 3 (2024): September Vol 18, No 2 (2024): June Vol 18, No 1 (2024): March Vol 17, No 4 (2023): December Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name Bayu Brahma

Contact Email journal.cancer@gmail.com

Phone +628176389956

Journal Mail Official admin@indonesianjournalofcancer.or.id

Editorial Address National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location Kota adm. jakarta barat, Dki jakarta INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA